|Bid||5.57 x 900|
|Ask||5.61 x 1100|
|Day's Range||5.35 - 5.62|
|52 Week Range||4.07 - 13.00|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AC Immune (ACIU) delivered earnings and revenue surprises of -16.67% and 32.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of AC Immune (NASDAQ:ACIU) remained unaffected after the company reported Q3 results.Quarterly Results Earnings per share were down 204.00% over the past year to ($0.26), which beat the estimate of ($0.28).Revenue of $1,223,000 declined by 96.38% from the same period last year, which beat the estimate of $930,000.Guidance Earnings guidance hasn't been issued by the company for now.View more earnings on ACIUAC Immune hasn't issued any revenue guidance for the time being.Price Action Company's 52-week high was at $13.00Company's 52-week low was at $4.07Price action over last quarter: down 21.52%Company Overview AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.See more from Benzinga * Click here for options trades from Benzinga * Recap: Vipshop Holdings Q3 Earnings * Earnings Scheduled For November 13, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.